{"title":"Degarelix: a new hormonal treatment for prostate cancer","authors":"Professor Malcolm Mason","doi":"10.1002/fps.42","DOIUrl":null,"url":null,"abstract":"<p>According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.<sup>1</sup> The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"11-15"},"PeriodicalIF":0.0000,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.42","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.42","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.1 The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.
Degarelix:一种治疗前列腺癌的新激素
根据NICE的数据，前列腺癌占英格兰和威尔士男性恶性癌症新诊断病例的25%。1癌症药物支出的最大单一领域是激素治疗，约占2.92亿英镑总额的40%。这篇文章的重点是一种新的激素治疗前列腺癌，degarelix。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
